Navigation Links
FDA Approves Xgeva to Help Prevent Cancer-Related Bone Injury
Date:11/19/2010

SILVER SPRING, Md., Nov. 19, 2010 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved Xgeva (denosumab) on Thursday to help prevent skeletal-related events (SREs) in patients with cancer that has spread (metastasized) and damaged the bone. Skeletal-related events include bone fractures from cancer and bone pain requiring radiation.

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Xgeva is a monoclonal antibody that targets a protein involved in cancer-related bone destruction called human RANKL. Other FDA-approved drugs for similar conditions include Zometa (zoledronic acid) and Aredia (pamidronate disodium).

Xgeva is not approved for patients with multiple myeloma or other cancers of the blood.

"Bone metastases represent a major cause of pain and suffering in patients with cancer and can affect a patient's quality of life," said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "Xgeva has a different mechanism of action than currently approved drugs aimed at reducing bone complications from cancer."

Xgeva's safety and effectiveness were confirmed in three randomized, double-blind clinical studies in 5,723 patients comparing Xgeva with Zometa. One study involved patients with breast cancer, another in patients with prostate cancer, and a third included patients with a variety of other cancers.

The studies were designed to measure the time until occurrence of a fracture or spinal cord compression due to cancer or until radiation or surgery for control of bone pain was needed.

In patients with breast or prostate cancers, Xgeva was superior to Zometa in delaying SREs. In men with prostate cancer, the median time to an SRE was 21 months with Xgeva compared to 17 months with Zometa.

In patients with breast cancer, the median time to an SRE was 26 months with Zometa and has not yet been reached with Xgeva. In patients with other solid tumors, time to development of an SRE was similar for both Xgeva and Zometa. The most common solid tumors were non-small cell lung cancer, multiple myeloma, kidney (renal) cancer, and small cell lung cancer.

The most serious side effects experienced with Xgeva were low calcium levels in the blood (hypocalcemia), and osteonecrosis of the jaw, a severe disease resulting from reduced blood flow to areas of the jaw and exposed jaw bone, causing pain, swelling, numbness, or infection.

Denosumab was originally approved under another trade name, Prolia, in June 2010. Prolia is indicated to treat postmenopausal women with osteoporosis who are at high risk for bone fractures. Xgeva is administered using a higher dose and with more frequent dosing than Prolia. Denosumab has a different safety profile in patients with osteoporosis than in patients with cancer and bone metastases.

Xgeva is marketed by Thousand Oaks, Calif.-based Amgen.

For more information:

FDA: Office of Oncology Drug Products

http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

FDA: Approves New Injectable Osteoporosis Treatment for Postmenopausal Women (Prolia)

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm214150.htm

Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA




'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves New Treatment Option for Late-Stage Breast Cancer
2. FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
3. FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain
4. FDA Approves New Indication for Afinitor
5. FDA Approves Teflaro for Bacterial Infections
6. FDA Approves Latuda to Treat Schizophrenia in Adults
7. FDA Approves Additional Medical Indication for Sprycel
8. FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
9. FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation
10. FDA Approves Botox to Treat Chronic Migraine
11. FDA Approves Injectable Drug to Treat Opioid-Dependent Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... LAKE OSWEGO, Ore. , May 3, 2016 ... and endovascular medical technology, today announced Food and ... a cardiac resynchronization defibrillator that provides heart failure ... (MRI) scans. Iperia devices also have remote monitoring ... (CLS) that adapts the heart rate in response ...
(Date:5/3/2016)... YORK , May 3, 2016 ... (MRI) Market Size, Share, Development, Growth and Demand Forecast ... Open), by Field Strength (High Field, Very High Field, ... Application (Brain, Head and Neck, Spine, Musculoskeletal, Vascular, Breast, ... the global magnetic resonance imaging (MRI) market was valued ...
(Date:5/3/2016)... LONDON , May 3, 2016 /PRNewswire/ ... gaben heute bekannt, dass sie einen entscheidenden ... erreicht haben: Ein Aufruf zum Handeln, um ... Diese Veröffentlichung trägt zu Fortschritten im Verständnis ... Notwendigkeit hervor, ein Bewusstsein für Hepatische Enzephalopathie ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... 04, 2016 , ... An accurate diagnosis is critical to ... community through expanding activities that embrace training, standards, technology and new methods of ... , In support of this important work, ASCP is co-sponsoring the inaugural ...
(Date:5/3/2016)... SCOTTSDALE, AZ (PRWEB) , ... May 03, 2016 ... ... NCPDP presented its 2016 Champion Award to Charles D. Pulido, R.Ph., ... Tricia Lee Wilkins, Pharm.D., M.S., Ph.D., Pharmacy Advisor and Health IT Specialist, Office ...
(Date:5/3/2016)... ... May 03, 2016 , ... Calvary Hospital recently hosted ... Greene Hospice (DGH), a 10-bed unit located at Mary, Manning Walsh Home (MMW) in ... (MSM) performs at DGH for half an hour, once a week. The music brings ...
(Date:5/3/2016)... ... May 03, 2016 , ... Sandbox, one ... Ferrazano to serve in the newly created position of executive vice president, chief ... creative efforts in the Chicago and LA offices. He reports to Nancy Finigan, ...
(Date:5/3/2016)... ... 2016 , ... University of the People, the world’s first ... Associates and Bachelor's degrees in Health Studies. Leading figures are heading the program’s ... Wiesel; Chairman and CEO of Fortune 500® company Henry Schein, Stanley M. Bergman; ...
Breaking Medicine News(10 mins):